Does tirzepatide actually reduce alcohol cravings?
The strongest evidence comes from a 2023 study that combined social media analysis with a controlled remote study [1]. In the remote study, 153 adults with obesity who were current drinkers either took tirzepatide (a GLP-1/GIP agonist) or semaglutide (a GLP-1 agonist) for at least 30 days, or took no medication. Compared to their own drinking before starting the medication and to the control group, the medication group reported significantly lower alcohol intake, fewer drinks per drinking episode, and lower scores on the Alcohol Use Disorders Identification Test (AUDIT) [1]. They also reported less of the stimulating and sedative effects of alcohol, which are linked to craving and continued use.
The social media analysis in the same study examined roughly 68,250 posts about GLP-1 or GLP-1/GIP agonists on Reddit. Among the 1,580 posts specifically about alcohol, 71% described reduced craving, decreased desire to drink, or other negative effects on drinking [1]. This large-scale, real-world data strongly suggests that tirzepatide can dampen alcohol cravings in people with obesity who drink alcohol.
How might tirzepatide affect cravings through the gut-brain axis?
A 2023 study on alcohol use disorder (AUD) patients found that alcohol craving is strongly linked to gut dysfunction and inflammation [2]. In 48 AUD patients, those with higher craving scores (Penn-Alcohol Craving Scale > 5) showed a strong association between craving and markers of gut dysregulation (like lipopolysaccharide binding protein and leptin) and proinflammatory markers (IL-1β and TNF-α) [2]. This gut-brain axis pathway explained 95.5% of the variance in heavy drinking days among those with high cravings [2].
Tirzepatide works by mimicking hormones (GLP-1 and GIP) that are naturally released from the gut after eating. These hormones signal the brain to reduce appetite and food intake. The same gut-brain signaling pathways are implicated in alcohol craving [2]. So, while the 2023 AUD study did not test tirzepatide, its findings suggest that medications that modulate gut-brain signaling—like tirzepatide—could plausibly reduce cravings by acting on these same biological pathways. This provides a mechanistic explanation for the real-world reductions in alcohol craving seen in the tirzepatide study [1].
Does tirzepatide reduce cravings for addictive foods?
None of the three studies directly tested tirzepatide's effect on cravings for addictive foods (like sugar, fat, or highly processed snacks). The 2023 study on tirzepatide focused exclusively on alcohol consumption [1]. The other two studies examined alcohol withdrawal and craving in AUD patients, not food addiction [2][3].
That said, tirzepatide is FDA-approved for weight management and type 2 diabetes, and it works by reducing appetite and slowing stomach emptying. Many people taking it report a general reduction in food cravings, but this has not been specifically studied for 'addictive foods' in a controlled trial. So, while it is plausible that tirzepatide could reduce cravings for addictive foods—given its mechanism of action and its effects on alcohol craving—there is currently no direct evidence to confirm this. The question remains open.
About These Sources
This answer is built on 3 peer-reviewed studies — published from 2021 to 2023, 1 in Q1 journals, collectively cited 127 times — selected as the most relevant from 3 studies that passed quality screening, drawn from 49 papers retrieved from a database of over 500 million.
Sources used in this answer
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
In a 2023 study combining social media analysis (68,250 posts) and a remote study (153 participants), people with obesity taking tirzepatide or semaglutide reported significantly lower alcohol intake, fewer binge-drinking episodes, and reduced alcohol cravings compared to before starting the medication and to a control group. Among 1,580 alcohol-related social media posts, 71% described reduced craving or desire to drink.
Novel paradigms for the gut–brain axis during alcohol withdrawal, withdrawal-associated depression, and craving in patients with alcohol use disorder
A 2023 study of 48 alcohol use disorder patients found that alcohol craving was strongly linked to gut dysfunction and inflammation (gut-brain axis), with a model explaining 95.5% of the variance in heavy drinking days among those with high cravings. This suggests that medications targeting gut-brain signaling, like tirzepatide, could reduce cravings.
Calcium Carbonate Attenuates Withdrawal and Reduces Craving: A Randomized Controlled Trial in Alcohol-Dependent Patients
A 2021 randomized controlled trial in 55 alcohol-dependent patients found that calcium carbonate (800 mg + vitamin D) during withdrawal led to faster reduction in withdrawal intensity and significantly lower alcohol craving compared to sodium bicarbonate, supporting the role of calcium in craving reduction.